COVID-19 vaccine (inactivated, adjuvanted, adsorbed)

USDailyMed:Biothrax J07AC01(WHO) CA:℞-onlyUS:℞-only DB11003Y none 873OI62848 Anthrax vaccine adsorbed, sold under the brand nameBiothraxamong others, is avaccineintended to provideacquired immunityagainstBacillus anthracis. Anthrax vaccine adsorbed originated in studies done in the 1950s and was first licensed for use in humans in 1970. In the US, the principal purchasers of the vaccine are theDepartment of DefenseandDepartment of Health and Human Services. Ten million courses (60 million doses) of the vaccine have been purchased for the USStrategic National Stockpilein anticipation of the need for mass vaccinations owing to a futurebio-terroristanthrax attack. The product has attracted some controversy owing to alleged adverse events and questions as to whether it is effective against the inhalational form of anthrax.